Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupDVHGF 56 Cash Ratio is 0.45 as of Apr. 2026, which is at its 10-year median of 0.45. GuruFocus rates DVHGF with a GF Score™ of 56/100 and a GF Value™ of $2.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,377 Biotechnology companies, Devonian Health Group ranks worse than 84.1% on this metric.
Devonian Health Group has a Cash Ratio of 0.45. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Devonian Health Group's Cash Ratio or its related term are showing as below:
DVHGF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.06 Med: 0.45 Max: 8.46
Current: 0.45
During the past 12 years, Devonian Health Group's highest Cash Ratio was 8.46. The lowest was 0.06. And the median was 0.45.
DVHGF's Cash Ratio is ranked worse than 84.1% of 1377
companies
in the Biotechnology industry
Industry Median: 2.96
vs DVHGF: 0.45
Devonian Health Group (OTCPK:DVHGF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Devonian Health Group's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (DVHGF) has a Cash Ratio of 0.45 as of Apr. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Devonian Health Group and its competitors. This is near median its historical median of 0.45. Over the past decade, Devonian Health Group's Cash Ratio has ranged from 0.06 to 8.46. According to the industry distribution chart, Devonian Health Group ranks #1158 out of 1377 companies in the Biotechnology industry, placing it in the top 84.1%.
Is Devonian Health Group's Cash Ratio too high?
Devonian Health Group's current Cash Ratio of 0.45 is near median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 8.46. The Biotechnology industry median Cash Ratio is 2.96. Devonian Health Group's value of 0.45 is 84.8% below this industry median. Based on the distribution chart, Devonian Health Group ranks #1158 out of 1377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Devonian Health Group has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #1158 out of 1377 companies for Cash Ratio. This places Devonian Health Group in the lower half of its industry. The industry median Cash Ratio is 2.96. Devonian Health Group's value of 0.45 is 84.8% below this benchmark. Historically, Devonian Health Group's own Cash Ratio has ranged from 0.06 to 8.46 over the past decade. While the company's 10-year median is 0.45 vs. the industry median of 2.96, Devonian Health Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,377 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devonian Health Group's current Cash Ratio of 0.45 is 84.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current Cash Ratio is 0.45, which is near median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.02, compared to a current price of $7.00 — trading 246.5% above its estimated fair value. The current Cash Ratio is 0.45, which is near median its 10-year median of 0.45 and 84.8% below the Biotechnology industry median of 2.96. Devonian Health Group's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Cash Ratio is 0.45 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 246.5% above its estimated GF Value™ of $2.02.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
Cash Ratio: 0.45 (near median its 10-year median of 0.45)
GF Value™: $2.02 vs. price of $7.00 (246.5% above fair value)
Industry Position: 84.8% below the Biotechnology median (#1158 of 1377)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
56GF Score
Get the complete analysis for DVHGF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
